Premium
High‐dose gadoteridol in MR imaging of intracranial neoplasms
Author(s) -
Runge Val M.,
Kirsch John E.,
Burke Vickie J.,
Price Ann C.,
Nelson Kevin L.,
Thomas Greg S.,
Dean Bruce L.,
Lee Charles
Publication year - 1992
Publication title -
journal of magnetic resonance imaging
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.563
H-Index - 160
eISSN - 1522-2586
pISSN - 1053-1807
DOI - 10.1002/jmri.1880020103
Subject(s) - medicine , nuclear medicine , radiology
Twelve patients with a high suspicion of brain metastases by previous clinical or radiologic examinations were studied in a phase III investigation with magnetic resonance (MR) imaging at 1.5 T after a bolus intravenous injection of 0.1 mmol/kg gadoteridol followed at 30 minutes by a second bolus injection of 0.2 mmol/kg gadoteridol. All lesions were best demonstrated (showed greatest enhancement) at the 0.3‐mmol/kg (cumulative) dose, with image analysis confirming signal intensity enhancement in the majority of cases after the second gadoteridol injection. More lesions were detected with the 0.3‐mmol/kg dose than with the 0.1‐mmol/kg dose, and more lesions were detected with the 0.1‐mmol/kg dose than on precontrast images. In this limited clinical trial, high‐dose gadoteridol injection (0.3‐mmol/kg cumulative dose) provided improved lesion detection on MR images specifically in intracranial metastatic disease.